(Total Views: 330)
Posted On: 10/08/2018 9:58:14 AM
Post# of 72447
$700mm is what Celgene gave UPFRONT for a Crohns drug that was going to enter Phase3. There was another $800mm of Milestones then another 25% of sales. Total deal ,NOT buyout was $2.5B.
BTW the drug failed interim P3 results. So the private company made $700mm.
Ya can't trust those PRIVATE companies!!!
BTW the drug failed interim P3 results. So the private company made $700mm.
Ya can't trust those PRIVATE companies!!!
(3)
(0)
